GHK-Cu and Warfarin Interaction: What Patients and Clinicians Need to Know

What the warfarin label says about new products

The warfarin label (Jantoven) says other drugs can change warfarin treatment through effects on clotting or through changes in warfarin exposure [3]. It says to perform regular INR monitoring in all treated patients, and more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when their doses change [3]. GHK-Cu is not named in the label's interaction examples, and the label says its CYP450 examples are not all-inclusive [3].

The boxed warning is about bleeding. Warfarin can cause major or fatal bleeding, and the label says drugs, dietary changes and other factors affect INR [3]. It also says to instruct patients on bleeding prevention and to report signs and symptoms of bleeding [3]. Bleeding is more likely in the first month. Named risk factors include an INR above 4.0, age 65 or older, a history of highly variable INRs, prior gastrointestinal bleeding, hypertension, anemia, malignancy, renal impairment, and certain concomitant drugs [3]. The label says that keeping the INR in the therapeutic range does not eliminate the risk of bleeding [3].

For botanicals specifically, the label says garlic and Ginkgo biloba can cause bleeding on their own and would be expected to add to warfarin's effect. It says co-enzyme Q10, St. John's wort and ginseng may decrease warfarin's effect [3]. Echinacea, grapefruit juice, ginkgo, goldenseal and St. John's wort can interact through CYP450 [3]. The label also notes that few adequate controlled studies of botanicals exist and that the amount of active ingredient in these products varies [3].

A small crossover study shows how measurable a plant product's effect can be. In 12 healthy men given a single 25 mg warfarin dose, 14 days of St. John's wort raised the apparent clearance of S-warfarin by 29 percent (ratio 1.29, 90 percent CI 1.16 to 1.46) and of R-warfarin by 23 percent. The INR area under the curve fell to 0.79 of baseline (90 percent CI 0.70 to 0.95) [7]. That finding is for St. John's wort, not GHK-Cu, and it says nothing about the peptide.

What GHK-Cu is and how it is regulated

GHK-Cu is the copper(II) complex of GHK, a tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva and urine, with levels reported to decline with age [8]. No FDA-approved drug is known to contain GHK-Cu [1][2]. It is a different compound from copper histidinate (Zycubo), which was approved in January 2026 for Menkes disease in children [2].

Topical creams and serums with copper peptide are sold as cosmetics, and cosmetics do not need FDA approval before they are sold [9]. HealthRX.com offers copper peptide cream as a topical product. Whether a product is a cosmetic or a drug turns on its intended use: claims to treat disease or to change the structure or function of the body make it a drug [9]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [9].

For compounding, FDA's interim policy places GHK-Cu (except for injectable routes of administration) in category 1, the group under evaluation for the bulks list. FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [1][10]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the bulks list, and no vote has happened yet [1]. Injectable GHK-Cu sits in FDA's nominated-but-withdrawn table. There, FDA states that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity from aggregation and peptide-related impurities, and that there are limited human data on safety [6].

What the human GHK-Cu studies measured

The human evidence is small and topical. In a randomized trial of 13 patients whose skin around the mouth was resurfaced with a CO2 laser, computer analysis and blinded evaluators found no significant difference in redness resolution or wrinkles between those using GHK-Cu skin care and those not. A patient questionnaire showed a significant difference in overall skin quality favoring GHK-Cu (P=.04) [4].

In a randomized, evaluator-blinded trial of 86 evaluable patients with venous stasis ulcers, a 0.4 percent tripeptide copper complex cream was no different from an inert vehicle for ulcer size, while silver sulfadiazine 1 percent did reduce ulcer size [5].

A 2026 systematic review retained 64 records published between 2005 and 2026. It concluded that the human literature remains thin and fragmented: most randomized trials are small and run on facial cosmetic creams, and microneedle delivery has not been tested in a single registered, adequately powered human randomized trial [11].

The mechanisms usually cited for GHK-Cu come from laboratory and animal work summarized by the researchers who proposed them. They include collagen and proteoglycan stimulation, modulation of metalloproteinases, attraction of immune and endothelial cells to injury sites, and faster wound healing in dogs, rats, mice and pigs [8]. These are preclinical findings, not demonstrated effects on human clotting.

Bottom line

No interaction between GHK-Cu and warfarin has been demonstrated, and none has been ruled out. The human GHK-Cu trials measured skin and ulcer outcomes, not INR or clotting [4][5]. The warfarin label's instruction is regular INR monitoring for everyone treated, with more frequent monitoring when another drug or botanical is started or stopped or its dose changes [3].